Pfizer and BioNTech Call for Dismissal of GSK’s COVID-19 Patent Challenge in Delaware Court

In a recent legal development, Pfizer Inc. and BioNTech have requested that a Delaware federal judge dismiss GlaxoSmithKline’s (GSK) attempt to invalidate allegations concerning COVID-19 vaccine technology patents. GSK has claimed that these patents, which they accuse Pfizer and BioNTech of infringing upon, are unenforceable due to an alleged unreasonable delay in their acquisition. This legal battle underscores the ongoing complexities surrounding intellectual property issues in the pharmaceutical industry as companies continue to innovate in response to global health crises. For more details on this matter, please refer to the article on Law360.